Editorial: Therapeutic potential of the cannabinoid CB2 receptor

• Reem Smoum,
• Uwe Grether,
• Meliha Karsak,
• Andrea J. Vernall,
• Frank Park,
• Cecilia J. Hillard,
• Pal Pacher

Affiliations

Reem Smoum

School of Pharmacy, The Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel

Uwe Grether

Roche Innovation Center Basel, F. Hoffman-La Roche Ltd., Basel, Switzerland

Meliha Karsak

Neuronal and Cellular Signal Transduction, Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Andrea J. Vernall

Department of Chemistry, University of Otago, Dunedin, New Zealand

Frank Park

Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States

Cecilia J. Hillard

Department of Pharmacology and Toxicology, Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, United States

Pal Pacher

Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/NIAAA, Rockville, MD, United States